A detailed history of Carr Financial Group Corp transactions in Moderna, Inc. stock. As of the latest transaction made, Carr Financial Group Corp holds 3,156 shares of MRNA stock, worth $124,946. This represents 0.06% of its overall portfolio holdings.

Number of Shares
3,156
Previous 4,309 26.76%
Holding current value
$124,946
Previous $512 Million 58.78%
% of portfolio
0.06%
Previous 0.16%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

SELL
$63.64 - $125.14 $73,376 - $144,286
-1,153 Reduced 26.76%
3,156 $211 Million
Q3 2023

Nov 06, 2023

BUY
$96.41 - $126.61 $84,840 - $111,416
880 Added 25.66%
4,309 $334 Million
Q2 2023

Jul 14, 2023

BUY
$118.5 - $160.53 $237,000 - $321,060
2,000 Added 139.96%
3,429 $417 Million
Q1 2023

Apr 19, 2023

SELL
$135.66 - $197.02 $3,391 - $4,925
-25 Reduced 1.72%
1,429 $219 Million
Q4 2022

Feb 13, 2023

BUY
$118.38 - $210.04 $172,124 - $305,398
1,454 New
1,454 $261 Million

Others Institutions Holding MRNA

About Moderna, Inc.


  • Ticker MRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 391,200,000
  • Market Cap $15.5B
  • Description
  • Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...
More about MRNA
Track This Portfolio

Track Carr Financial Group Corp Portfolio

Follow Carr Financial Group Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Carr Financial Group Corp, based on Form 13F filings with the SEC.

News

Stay updated on Carr Financial Group Corp with notifications on news.